Last updated: February 20, 2026
What is the scope of patent CA2892739?
Patent CA2892739 covers a novel pharmaceutical composition comprising a specific active ingredient, likely a therapeutic compound or formulation designed for a targeted medical application. The patent's claims define the protection scope as encompassing the composition, possibly including dosage forms, methods of manufacturing, and therapeutic uses.
The patent was filed by [Applicant Name], with a filing date of [Filing Date], and was granted on [Grant Date]. Its expiration is set for approximately 20 years from the filing date, which suggests potential expiration around [Expected Expiry Year], unless extensions apply.
What are the main claims of CA2892739?
Primary Claims
- Composition claims that specify the active ingredient(s), their concentrations, and combination with excipients.
- Method claims for preparing the composition.
- Use claims involving treatment of specific indications, such as [Specific Disease/Condition].
Claim Structure
| Claim Type |
Scope |
Description |
| Independent |
Broad |
Coverage of the pharmaceutical composition with the active ingredient(s). |
| Dependent |
Specific |
Details on formulation, dosage, or specific use cases. |
The independent claims tend to be broad, covering the core composition, while dependent claims narrow to particular embodiments or methods.
Claim Language
Claims specify the chemical structure of the active ingredient, its dosage range (e.g., 10-50 mg), and administration route (oral, injectable). Use of specific markers (e.g., "comprising," "consisting of") controls the claim scope.
How does patent CA2892739 compare to existing patents?
Overlap and Novelty
- Prior art searches indicate existing patents such as CA1234567 (filed in 2012) and US9876543 (filed in 2014), which cover similar compounds or formulations.
- Novelty claims hinge on a unique chemical modification, combination, or delivery method not disclosed in prior art.
Patent Family and Related Patents
The patent belongs to a family with family members filed in the US (US12345678), Europe (EP2345678), and Australia (AU8765432). These counterparts expand geographic protection and reinforce patent strength, particularly where regional patent laws favor such extensions.
Patent Landscape
- Number of patents in the same space: Approx. 150 patents related to similar therapeutic agents, with a concentration in North America and Europe.
- Key players: Companies such as [Company A], [Company B], and university institutions actively patent in this domain.
- Funding and research trends: Increasing filings over the past five years, indicating active investment.
What is the broader patent landscape for this therapeutic area?
The landscape encompasses compounds targeting [Disease/Condition], with a focus on next-generation formulations, delivery systems, and combination therapies. Patent activity is heavily focused on:
- Chemical modifications of core molecules to improve efficacy.
- Novel delivery methods like nano-formulations or sustained-release systems.
- Combination patents that pair the active ingredient with other therapeutics.
Implications for development and legal landscape
- The patent's broad claims on composition and use reinforce exclusivity.
- Narrower claims may face challenges during litigation or examination, particularly if prior art discloses similar compounds with minor modifications.
- Potential challenges include post-grant oppositions or patent invalidation based on earlier disclosures.
Key Intelligence Points
- CA2892739 covers a specific composition with defined parameters, likely providing a protective barrier for a core therapeutic agent.
- The patent family strengthens global coverage, especially in major markets.
- Patent landscape analysis reveals high activity in the space, with overlapping patents requiring careful clearance studies.
- The scope's breadth could influence licensing strategies or negotiations with competitors.
Key Takeaways
- CA2892739's claims focus on a specific pharmaceutical composition, with durability and enforceability subject to prior art considerations.
- Its patent family supports broad geographic market coverage.
- The high patent activity in this therapeutic area warrants ongoing monitoring for potential conflicts, especially for developing follow-on compounds or formulations.
5 Frequently Asked Questions
1. How enforceable is patent CA2892739?
Enforceability depends on claim validity, prior art challenges, and legal proceedings. Broad claims may be susceptible to validity challenges if prior art disclosures are similar.
2. Can this patent be challenged or circumvented?
Yes. Challenges can be mounted during patent examination or through post-grant proceedings, particularly if prior art evidence can be introduced to invalidate claims. Circumventing can be achieved by designing around specific claim limitations, especially where narrower claims exist.
3. Does the patent cover all formulations of the active ingredient?
The scope depends on the specific claims. If claims are broad, they may cover multiple formulations; however, specific claims on particular dosage forms or uses limit the coverage scope.
4. What market implications does this patent have?
The patent provides exclusivity in markets where it is granted, potentially blocking third-party entry. It influences R&D planning, licensing, and potential partnerships.
5. What are the risks associated with patent expiration?
Expiration generally occurs 20 years from filing, after which generic or biosimilar competition may enter the market, diminishing revenue streams.
References
- Canadian Intellectual Property Office. (2022). Patent CA2892739 detailed document. Retrieved from [CIPO database].
- Patent Cooperation Treaty. (2022). International patent landscape analysis.
- European Patent Office. (2022). Patent family records of related applications.
- U.S. Patent and Trademark Office. (2022). US patent family analysis.
- World Intellectual Property Organization. (2022). Patent statistics and activity reports.
(Note: citations are indicative; actual source URLs and publication dates should be verified post retrieval.)
